Clinical trials: Hepatitis C, completed
Hepatitis C, Chronic
A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection
This study will evaluate the addition of a higher-dose induction treatment period with peginterferon (PEG-IFN) alfa-2a (Pegasys) and ribavirin prior to standard-dose treatment with PEG-IFN alfa-2a and ribavirin, compared to…
- Trial name
- NCT00192647
- Testing
- PEG-IFN alfa-2a, Ribavirin
- Where
- 51 sites in Argentina, Australia and 4 more
- Volunteers
- 896 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
This randomized, open-label, active-controlled, parallel-group study will evaluate the sustained virological response of danoprevir boosted with low dose ritonavir in combination with Pegasys (peginterferon alfa-2a) and Copegus…
- Trial name
- NCT01220947
- Testing
- Copegus, Danoprevir, Pegasys
- Where
- 68 sites in United States, Austria and 9 more
- Volunteers
- 421 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Hepatitis B
Study to Evaluate the Prevalence of Hepatitis C in Spain in 2015 (PREVHEP)
The hypothesis of this investigation stresses that the current understanding of the prevalence of HCV infection in the general population and in different subgroups will serve to lay out medium- and long-term measures for action…
- Trial name
- PREVHEP (NCT02749864)
- Where
- 3 sites in Spain
- Volunteers
- 12,246 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Sperm Motility (Focus of Study)
Influence of Ribavirin and Interferon on Semen Quality, IRIS Study
The aim of this study is to study the effect of peginterferon alpha and ribavirin on spermatozoa.
- Trial name
- IRIS (NCT00455832)
- Testing
- peginterferon alpha and ribavirin
- Where
- Netherlands
- Volunteers
- 23 people
- Sponsor
- Foundation for Liver Research
Pruritus, Liver Cirrhosis, Biliary
Treatment of Cholestatic Pruritus With Sertraline
The goal of this study is to find an effective and well-tolerated medical therapy for itching due to liver disease. Persons with primary biliary cirrhosis or chronic hepatitis C are currently being enrolled in the study.
- Conditions
- Pruritus, Liver Cirrhosis, Biliary, Hepatitis C
- Trial name
- NCT00058903
- Testing
- sertraline
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV Infections, Hepatitis C
Tajik Migrant Health Education Study
This study will test the efficacy of a peer-education prevention intervention to reduce risky drug, alcohol, and sexual behaviors among male Tajik labor migrants who inject drugs (MWID) while working in Moscow.
- Conditions
- HIV Infections, Hepatitis C, Risky Health Behavior, Risk Reduction Behavior
- Trial name
- NCT04853394
- Testing
- MASLIHAT, TANSIHAT
- Where
- Russia
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Hepatitis C, Substance Use Disorders
Opportunstic Hepatitis C Virus Treatment
The project will assess the effect of opportunistically treating hepatitis C virus (HCV) infection immediately when HCV-infected people who inject drugs are hospitalized for acute care in psychiatric, interdisciplinary…
- Trial name
- Opportuni-C (NCT04220645)
- Testing
- Opportunstic treatment, Standard of care
- Where
- Norway
- Volunteers
- 218 people
- Sponsor
- University Hospital, Akershus
Heart Failure
Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)
This study is being conducted to determine safety and effectiveness of transplanting hearts from Hepatitis C-positive donors into Hepatitis C-negative patients on the heart transplant waitlist, who will then be treated with…
- Trial name
- USHER (NCT03146741)
- Testing
- Zepatier
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
Hepatitis C, Liver Diseases
Improving Hepatitis C Treatment in Injection Drug Users
The overall goal of the research project is to improve the outcome of medical care for injection drug users (IDUs) with Hepatitis C viral (HCV) infection.
- Conditions
- Hepatitis C, Liver Diseases, Drug Abuse, Alcoholism
- Trial name
- NCT00148031
- Testing
- Pegylated Interferon and Ribavirin, Psychosocial, On-site (MMT Clinic) HCV evaluation and treatment
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- State University of New York - Upstate Medical University
Hepatitis C
Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects
The primary purpose of this study is to assess the effect of the Daclatasvir/Asunaprevir/BMS-791325 fixed dose combination (FDC) tablet on the pharmacokinetics of the cocktail CYP and transporter probe substrates and to assess…
- Trial name
- NCT02045966
- Testing
- Cocktail, DCV 3DAA FDC, BMS-791325
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
This open-label, parallel cohort study will evaluate the safety, pharmacokinetics and antiviral activity of ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and ribavirin in treatment-naïve…
- Trial name
- NCT01483742
- Testing
- RO5024048, danoprevir, peginterferon alfa-2a [Pegasys]
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)
This retrospective study will assess the sustained virologic response and the safety of two different interferons (pegylated or conventional) in patients with chronic hepatitis C. Data will be collected for 24 weeks.
- Trial name
- NCT01280656
- Testing
- Conventional Interferon, Peginterferon Alfa-2a, Peginterferon Alfa-2b
- Where
- 37 sites in Brazil
- Volunteers
- 660 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Renal Cell Carcinoma
Association Between Hepatitis C Infection and Renal Cell Carcinoma
The purpose of this study is to determine if there is an association between hepatitis C infection and kidney cancer. All patients who are diagnosed with kidney cancer and who will either have a biopsy or surgery will be offered…
- Conditions
- Hepatitis C, Renal Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT01405183
- Testing
- Hepatitis C testing
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Henry Ford Health System
Hepatitis C Virus
Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3
The primary objective of the study is to demonstrate that the efficacy of peginterferon alfa-2a 40KD combination therapy with ribavirin in interferon naïve patients with chronic hepatitis C virus infection genotype 2 or 3 given…
- Trial name
- NCT00143000
- Testing
- Peginterferon alfa-2a 40KD and Ribavirin
- Where
- Sweden
- Volunteers
- 392 people
- Sponsor
- NORDynamIC Study Group
Hepatitis C
Anti-E1E2 Antibodies (D32.10 Epitope-binding Antibodies) and HCV Triple Therapy
The hypothesis was to check whether baseline anti-E1E2 antibodies were correlated with the on-treatment viral kinetics and could predict virological outcome in treatment-experienced HCV-infected cirrhotic patients receiving…
- Trial name
- NCT02877199
- Testing
- Triple therapy
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Hospices Civils de Lyon
Chronic Hepatitis C
Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy
A short 14 day phase 1 study examining 6 monotherapy doses of oral tamoxifen for safety in chronic HCV patients who have failed standard treatment of peginterferon and ribavirin.
- Trial name
- NCT00749138
- Testing
- tamoxifen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Bader, Ted, M.D.
Hepatitis C
The Sublimated Mare Milk Supplement in Hepatitis C
This clinical trial studies the effect of sublimated mare milk supplement on patients with hepatitis C.
- Trial name
- NCT03669835
- Testing
- Mare milk supplement, Standard therapy
- Where
- Kazakhstan
- Volunteers
- 100 people
- Sponsor
- Asfendiyarov Kazakh National Medical University
Hepatitis C, Chronic, Genotype 1
Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)
The primary objective of this study is to evaluate the impact of chronic hepatitis C (CHC), and the treatment thereof with peginterferon alpha-2b (PEG) and ribavirin (RBV) according to standard clinical practice, on the…
- Conditions
- Hepatitis C, Chronic, Genotype 1, HCV-1
- Trial name
- VIDA (NCT00863109)
- Testing
- Peginterferon alfa-2b (PEG), Ribavirin (RBV)
- Volunteers
- 133 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus (HCV)
Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection
This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with compensated cirrhosis with or without human…
- Trial name
- VOYAGE-2 (NCT03235349)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 34 sites in China, South Korea
- Volunteers
- 160 people
- Sponsor
- AbbVie
Hepatitis C
A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
This is a study of the safety and efficacy of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) ± ribavirin (RBV). The primary efficacy endpoint will be Sustained Virologic Response 12 weeks after the end of all study…
- Trial name
- C-WORTHy (NCT01717326)
- Testing
- Grazoprevir, Elbasvir, Ribavirin
- Volunteers
- 573 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.